Abstract 207P
Background
Immune checkpoint inhibitors (ICIs) pushed therapeutic strategy of NSCLC into a new era. Nevertheless, the clinical benefit of ICI therapy in EGFR-driven NSCLC patients, especially patients resistant to EGFR-TKI was unsatisfactory. Immunosuppressive tumor microenvironment (TME) after EGFR-TKI treatment proved huge influence on the efficacy of ICIs. Investigation of the mechanism underlying suppressive TME and exploration of its potential intervention was the urgent requirement for EGFR-TKI resistant NSCLC research.
Methods
ZEB2 expression in NSCLC cell lines and patients’ samples were assessed utilizing qRT-PCR, western blotting, and IHC. The effect of EGFR-TKI resistance and ZEB2 on TAMs polarization were investigated via qRT-PCR of M1/M2 biomarkers and flow cytometry. The modulation of ZEB2 on cytokines’ secretion was evaluated through qRT-PCR, ELISA and MSD. The direct influence of ZEB2 on promoter regions of cytokines was explored by dual luciferase reporter assay. The regulation of signaling pathway on ZEB2 was analyzed by correlative analysis, the results were consolidated using western blotting. Mouse models were used to further confirm the influence of EGFR-TKI resistance and ZEB2 on TAMs polarization.
Results
EGFR-TKI resistance induced M2 polarization and inhibited M1 polarization of TAMs, which was critical for the formation of immunosuppressive TME. ZEB2 was upregulated in EGFR-TKI resistant NSCLC in vitro, in vivo and in silicon. ZEB2 upregulation could induce M2 polarization and impede M1 polarization of TAMs, demonstrating its essential role in the influence of EGFR-TKI resistant NSCLC on TAMs polarization. Besides, ZEB2 overexpression was dependent on PI3K-Akt pathway which was upregulated after EGFR-TKI resistance in NSCLC. Finally, ZEB2's regulation on TAMs polarization was associated with cytokines’ secretion. Apart from its inducement on TGF-β1 secretion, ZEB2 directly bound to the promoter region of CSF-1 to elevate its secretion.
Conclusions
ZEB2, which was upregulated in EGFR-TKI resistant NSCLC on a PI3K-Akt dependent manner, could induce M2 polarization and hinder M1 polarization via elevating the secretion of CSF-1 and TGF-β1.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
43P - Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma
Presenter: Gang Chen
Session: Poster Display session
Resources:
Abstract
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract